4 results about "Vascular embolization" patented technology

The present invention relates to a temperature-responsive in situ gelling composition comprising an amphiphilic triblock copolymer of polyoxyethylene-polyoxypropylene-polyoxyethylene (PEO-PPO-PEO), a water-soluble hydrophilic polymer, wherein the composition further comprises at least one lipid agent. The lipid agent is selected from the group consisting of a phospholipid, a sterol, a glyceride, a fatty acid or ester and derivative, a fatty alcohol, a cholesterol and derivative or a combination of more than one lipid agent. The present invention further relates to a vascular embolization agent comprising the temperature-responsive in situ gelling composition.

This invention belongs to the field of biomedical technology, specifically disclosing an injectable embolic agent, its preparation method, and its application. The embolic agent is a hydrocolloid system containing core-shell structured nanoparticles: the core contains Cu... 2+ Salt and ATOX1 inhibitors, where ATOX1 inhibitors can inhibit copper ion efflux and promote intracellular copper accumulation, and interact with Cu 2+ It synergistically induces copper death in tumor cells; the shell is a thermosensitive block copolymer hydrogel that can interact with Cu. 2+ Coordination bonds are formed, enhancing the stability of nanoparticles, while a sol-gel transition occurs at physiological temperatures, enabling precise vascular embolization; the overall core-shell structure allows for the formation of Cu... 2+ The sustained-release effect of ATOX1 inhibitors was observed. In the VX2 rabbit hepatocellular carcinoma model, this embolization agent significantly improved tumor necrosis rate and reduced metastasis rate compared to traditional iodized oil embolization; it also downregulated hypoxia- and angiogenesis-related factors such as HIF-1α, VEGF, and CD31, inhibited MMP9-mediated tumor invasion and metastasis, and promoted CD8+. + T-cell infiltration effectively improves the tumor immunosuppressive microenvironment after transarterial chemoembolization.

This invention discloses the preparation and application of radiofrequency thermoresponsive platinum ion crosslinked black phosphorus nanogel. The nanogel has a core-shell structure, comprising a core composed of a radiofrequency thermosensitive agent and chemotherapeutic drugs, and a shell constructed from a thermosensitive nanopolymer. The thermosensitive nanogel BP-Pt@PNA prepared using the above components exhibits radiofrequency thermosensitive properties. Simultaneously, the introduction of the thermosensitive nanopolymer improves the stability of the radiofrequency thermosensitive agent and chemotherapeutic drugs, enabling long-term drug retention and fully leveraging the synergistic effect of non-invasive radiofrequency thermotherapy and chemotherapy. This drug-loaded nanogel can achieve multimodal treatment applications, including non-invasive radiofrequency thermotherapy-chemotherapy synergistic antitumor therapy and invasive radiofrequency ablation-chemotherapy-vascular embolization synergistic antitumor therapy, demonstrating significant clinical translational potential.

This invention provides a vascular embolization treatment device, relating to the field of vascular embolization medical device technology. It includes a delivery tube and a spring coil. The spring coil includes a spring coil body and an end fixed to the distal end of the spring coil body. It also includes an end control mechanism and a spring coil control mechanism, with the distal end of the end control mechanism detachably connected to the proximal end of the end. The distal end of the delivery tube is detachably connected to the proximal end of the spring coil body via the spring coil control mechanism. This invention can improve the success rate of spring coil formation, avoid mis-embolization, and reduce surgical risks.